Treats hypertension. ANDA 208920, held by Sciegen Pharms. Lisinopril.
As of Nov 14, 2026, ANDA 208920 (Lisinopril), held by Sciegen Pharms, was first approved by FDA on Mar 4, 2021, with 0 approved supplements and 0 published complete response letters.
Lisinopril tablets is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older Adjunct therapy for heart failure Treatment of Acute Myocardial Infarction
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 4, 2021 | Original application | Approved | None posted |
| Lisinopril20MG · tablet;oral | Lisinopril | Rx |
| Lisinopril30MG · tablet;oral | Lisinopril | Rx |
| Lisinopril40MG · tablet;oral | Lisinopril | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
